Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPURE.L Regulatory News (PURE)

  • There is currently no data for PURE

Trading Update - H1 FY 2012

12 Jan 2012 07:00

RNS Number : 4146V
PureCircle Limited
12 January 2012
 



PURECIRCLE LIMITED

("PureCircle" or the "Company")

TRADING UPDATE - H1 FY 2012

PureCircle (LSE: PURE), the world's largest producer and marketer of high purity stevia today provides a trading update in respect of the six month period from 1 July 2011 to 31 December 2011, being the first half of its Financial Year 2012 (1H FY 12). The Company's interim results for 1H FY 12 will be announced on Thursday 29 March 2012.

Sales

Sales were in line with expectations at $15m (H1 FY 11: $13m). There were no sales to the Company's Global Beverage Key Accounts (GBKA's) in H1, as they continue to use existing inventories. There was strong growth across the Group's new product range, particularly Natural Flavours and SG95 products. Alpha is receiving good market feedback. Launched in September 2011, this product will begin to make initial sales contributions in H2 FY 12. By region, sales saw strong growth in Latin America, Asia Pacific and some initial uptake in Europe. USA continues to grow, despite absence of sales to GBKA's, reflecting our increased diversified customer base.

One off costs

As reported in its FY 11 results, the Group has slowed down the production of Reb A temporarily across calendar 2011 so as to align inventories with current market demand. As a result production overheads and related costs have been charged to profit in H1 FY 12 that would ordinarily be charged to inventory. The one off costs are estimated at between $5 and $10m.

Foreign exchange

The Group has incurred foreign exchange costs of $3m (H1 FY 11 gains of $2.9m) on its fixed production economic hedges due to strengthening of the US$ against production currencies. This is expected to unwind, at least partially in H2 FY 12.

Operating margin and EBITDA

The Group's variable contribution and gross profit, before one off costs and foreign exchange, both strengthened in H1 FY 12 against H1 FY 11, reflecting improved product mix and lower variable costs.

Despite increased sales and marketing investments in our EU Joint Ventures ahead of the EU opening in December 2011, our general and administrative costs are expected to be lower than H1 FY 11. As a result, after adjusting for foreign exchange and one off costs, the Group expects to report improved operating margins and EBITDA against H1 FY 11.

Cash, net debt and funding headroom

The Group ends H1 FY12 with net debt of less than $72m (H1 FY 11 $77m). The positive operating cashflow across calendar 2011 principally reflects the reduction in inventories, which are expected to end 2011 at least $20m lower than their peak at 31 December 2010. In addition, with its $300m supply chain fully invested, the Group's capital expenditure requirements are low.

The Group has cash and facility headroom of more than $60m (H1 FY11 $50m) and is fully funded for its foreseeable growth plans.

Commenting on the H1 FY 12 trading, the Group CEO Magomet Malsagov said "Nielsen market data confirms there is continued strong growth in consumer market usage of high purity stevia based food and beverage products. Although our H1 FY12 sales were higher than comparable period in FY11, they were still modest as expected due to GBKA's inventories and late EU regulatory approval. With the EU market now open, with our new innovations clearly gaining market share and with our diversified customer base we expect an uptick in growth from H2 FY 12. However our guidance for sustained high levels of market demand remains mid to long term based."

Enquiries:

PureCircle Limited (www.purecircle.com)

Magomet Malsagov, CEO

+60 1 2388 8049

William Mitchell, CFO

+44 7974 005 163

RFC Corporate Finance (NOMAD)

+61 8 9480 2500

Steve Allen

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDFLFFLFFFBBB
Date   Source Headline
1st Jul 20205:10 pmRNSScheme of Arrangement becomes Effective
30th Jun 20206:00 pmRNSNew External Auditor Appointment
29th Jun 20205:45 pmRNSChanges in the Board Composition
26th Jun 20206:37 pmRNSCourt sanction of the Scheme
18th Jun 20205:47 pmRNSResults of Court Meeting and General Meeting
18th May 20205:45 pmRNSPublication of Scheme Document
7th May 20209:37 amRNSResults of Adjourned 2019 Annual General Meeting
7th May 20207:00 amRNSDispatch Date for Scheme Document
5th May 20202:31 pmRNSPDMR Notification
1st May 20207:00 amRNSBlock Listing Application
29th Apr 20207:00 amRNSNew Banking Facility
28th Apr 20203:22 pmRNSUpdate on Adjourned 2019 Annual General Meeting
20th Apr 20209:04 amRNSForm 8.3 - PureCircle Limited
20th Apr 20208:50 amRNSForm 8.3 - PureCircle Limited
20th Apr 20208:32 amRNSForm 8 (OPD) (PureCircle Limited)
16th Apr 20203:54 pmRNSForm 8.3 - PureCircle Limited
16th Apr 20203:08 pmRNSForm 8 (OPD) (PureCircle Limited)
16th Apr 20202:43 pmRNSForm 8.3 - PureCircle Limited
16th Apr 20202:40 pmRNSForm 8.3 - PureCircle Limited
16th Apr 20202:35 pmRNSForm 8.3 - PureCircle Limited
16th Apr 20202:30 pmRNSForm 8.3 - PureCircle Limited
15th Apr 20207:30 amRNSRestoration PureCircle Limited
9th Apr 20204:52 pmRNSNotice of Adjourned AGM and Annual Report
9th Apr 20202:07 pmRNSOffer for PureCircle Limited
9th Apr 20201:56 pmRNSUnaudited Interim Results and Trading Update
5th Mar 20207:00 amRNSCompany Update
5th Mar 20207:00 amRNSManagement Changes
19th Feb 20207:00 amRNSUpdate on lending facilities
10th Feb 20201:25 pmRNSResults of AGM and Directorate Change
4th Feb 20202:46 pmRNSCFO appointment effective
28th Jan 20203:45 pmRNSManagement Update
14th Jan 20204:42 pmRNSNotice of AGM and Company Update
3rd Jan 20202:00 pmRNSAppointment of CFO
2nd Jan 20207:00 amRNSBlock Listing Six Monthly Return
31st Dec 201912:15 pmRNSBoard Changes
27th Dec 20192:50 pmRNSManagement and Board Committee Changes
12th Dec 20192:40 pmRNSBoard and Management Changes
22nd Nov 20193:38 pmRNSResignation of a Director
20th Nov 20197:52 amRNSCorrection: Appointment of Directors
18th Nov 20193:42 pmRNSAppointment of Directors
14th Nov 20197:40 amRNSCompany Update
12th Nov 20192:52 pmRNSResignation of Director
28th Oct 20197:48 amRNSSuspension of share listing
25th Oct 20195:23 pmRNSPostponement of results and suspension of listing
23rd Oct 20194:35 pmRNSPrice Monitoring Extension
20th Sep 20194:40 pmRNSSecond Price Monitoring Extn
20th Sep 20194:35 pmRNSPrice Monitoring Extension
20th Sep 20194:15 pmRNSPostponement of Results
22nd Aug 20194:35 pmRNSPrice Monitoring Extension
16th Aug 20197:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.